18F-JK-PSMA-7用于前列腺癌PET/CT的首批人体观察研究及首年临床应用经验
该研究先在10例前列腺癌患者中头对头比较18F-JK-PSMA-7与68Ga-PSMA-11 PET/CT,显示前者不劣于后者;随后分析75例生化复发(BCR)患者临床18F-JK-PSMA-7 PET/CT数据,总病灶检出率84.8%,并按PSA分层报告检出率。结论认为该示踪剂安全、临床有用,推荐用于未来前瞻性试验。
要点
- 10例头对头研究中,18F-JK-PSMA-7不劣于68Ga-PSMA-11,且4例发现额外可疑PSMA阳性病灶。
- 75例生化复发患者中,18F-JK-PSMA-7 PET/CT检出至少一个PSMA阳性病灶的能力为84.8%。
- 前列腺切除术后按PSA分层检出率:PSA<0.5 μg/L为54.5%(6/11),0.5-2 μg/L为87.5%(14/16),>2 μg/L为90.9%(20/22)。
核心结论
- 18F-JK-PSMA-7安全且临床有用,在头对头研究中不劣于68Ga-PSMA-11,并在寡转移生化复发患者中识别出额外PSMA高摄取可疑病灶。
研究设计与样本
- 机构审查委员会批准的试点研究,10例前列腺癌患者间隔<3周分别接受18F-JK-PSMA-7与68Ga-PSMA-11 PET/CT直接比较。
- 随后分析75例因生化复发接受临床18F-JK-PSMA-7 PET/CT肿瘤定位的连续患者数据。
主要发现
- 10例头对头研究中,所有68Ga-PSMA-11明确阳性病灶均可被18F-JK-PSMA-7检出,4例发现额外可疑PSMA阳性病灶,1例由PSMA阴性转为阳性。
- 75例生化复发患者中,18F-JK-PSMA-7 PET/CT检出至少一个PSMA阳性病灶的能力为84.8%。
- 前列腺切除术后按PSA分层检出率:PSA<0.5 μg/L为54.5%(6/11),PSA 0.5-2 μg/L为87.5%(14/16),PSA>2 μg/L为90.9%(20/22)。
关键数值与推荐
- 生化复发(前列腺切除或放疗后)患者中,18F-JK-PSMA-7 PET/CT检出至少一个PSMA阳性病灶的能力为84.8%。
- 前列腺切除术后PSA<0.5 μg/L者检出率为54.5%(6/11),PSA 0.5-2 μg/L者为87.5%(14/16),PSA>2 μg/L者为90.9%(20/22)。
临床怎么用
- 18F-JK-PSMA-7可用于前列腺癌生化复发患者的PET/CT肿瘤定位,尤其在前列腺切除术后PSA≥0.5 μg/L时检出率较高。
- 对于68Ga-PSMA-11显像阴性或寡转移可疑的生化复发患者,18F-JK-PSMA-7可能发现额外PSMA阳性病灶。
- 该示踪剂被推荐用于未来前瞻性试验,当前证据来自小样本试点与单中心连续队列。
局限性
- 头对头比较仅纳入10例患者,样本量小。
- 临床队列为75例连续患者,来自单中心首年应用经验。
- 研究为观察性设计,结论尚需前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In preclinical trials, the recently developed tracer 2-methoxy-18F-DCFPyL (18F-JK-prostate-specific membrane antigen [PSMA]-7) has shown favorable properties regarding clinical performance and radiochemical accessibility. The aim of this study was to evaluate the clinical utility of 18F-JK-PSMA-7 for PET/CT imaging of patients with prostate cancer. Methods: In an Institutional Review Board-approved pilot study, the initial clinical utility of PET/CT imaging with 18F-JK-PSMA-7 was directly compared with 68Ga-PSMA-11 PET/CT in a group of 10 patients with prostate cancer. The 2 PSMA tracers were administered to each patient less than 3 wk apart. Next, we analyzed the data of 75 consecutive patients who had undergone clinical 18F-JK-PSMA-7 PET/CT imaging for tumor localization of biochemical recurrence (BCR). Results: The pilot study in 10 patients who were examined with both PSMA tracers demonstrated that 18F-JK-PSMA-7 was at least equivalent to 68Ga-PSMA-11. All unequivocally 68Ga-PSMA-11-positive lesions could be also detected using 18F-JK-PSMA-7, and in 4 patients additional suspected PSMA-positive lesions were identified (1 patient changed from PSMA-negative to PSMA-positive). In patients with BCR (after prostatectomy or radiotherapy), the capacity of 18F-JK-PSMA-7 PET/CT to detect at least one PSMA-positive lesion was 84.8%. The prostate-specific antigen (PSA)-stratified detection rate of 18F-JK-PSMA-7 after prostatectomy varied among 54.5% (6/11 patients; PSA < 0.5 μg/L), 87.5% (14/16 patients; PSA 0.5-2 μg/L), and 90.9% (20/22 patients; PSA > 2 μg/L). Conclusion: The tracer 18F-JK-PSMA-7 was found to be safe and clinically useful. We demonstrated that 18F-JK-PSMA-7 was not inferior when directly compared with 68Ga-PSMA-11 in a pilot study but indeed identified additional PSMA-avid suspected lesions in oligometastasized patients with BCR. In a subsequent analysis of a clinical cohort of BCR patients, 18F-JK-PSMA-7 was useful in tumor localization. 18F-JK-PSMA-7 is recommended for future prospective trials.
引用
- Dietlein F, Hohberg M, Kobe C, et al. An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application. J Nucl Med. 2019. PMID: 31324713. doi:10.2967/jnumed.119.229542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。